Progenity Inc. (PROG): Price and Financial Metrics
GET POWR RATINGS... FREE!
PROG Stock Price Chart Interactive Chart >
PROG Price/Volume Stats
|Current price||$0.88||52-week high||$6.20|
|Prev. close||$0.92||52-week low||$0.66|
|Day high||$0.92||Avg. volume||8,589,605|
|50-day MA||$1.17||Dividend yield||N/A|
|200-day MA||$1.85||Market Cap||162.92M|
Progenity Inc. (PROG) Company Bio
Progenity, Inc. engages in the provision of molecular and specialized diagnostic tests to clinicians. Its products include Preparent Carrier Test, Innatal Prenatal Screen, Riscover Hereditary Cancer, and Resura Prenatal Test. The company was founded by Paul W. Hawran and Harry Stylli in 2010 and is headquartered in San Diego, CA.
Most Popular Stories View All
PROG Latest News Stream
|Loading, please wait...|
PROG Latest Social Stream
View Full PROG Social Stream
Latest PROG News From Around the Web
Below are the latest news stories about Progenity Inc that investors may wish to consider to help them evaluate PROG as an investment opportunity.
Patient data establishes key correlations for therapeutic exposure in tissue and alternative inflammatory pathways, supporting the hypotheses of targeted therapeutic delivery and potential combination therapy for ulcerative colitisSAN DIEGO, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today shared two poster presentations that were presented during the 17th Congre
Progenity Shares Oral Presentation on Treatment of Gastrointestinal Disorders at 34th Belgian Week of Gastroenterology
Dr. Bram Verstockt presented key patient data establishing correlation between drug levels in colon and clinical outcomesSAN DIEGO, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today shared an oral presentation that was delivered by Dr. Bram Verstockt during the 34th edition of the Belgian Week of Gastroenterology on February 9, 2022. During the oral presentation t
After this past year, it's going to be hard to find stocks to buy to make you a millionaire in 2022.
Progenity Strengthens Intellectual Property for Single-Molecule Detection Technology with Additional Patent
SAN DIEGO, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, today announced the award of another new patent related to its single-molecule detection assay platform under development. The USPTO has issued U.S. Patent No. 11,230,731 entitled, “Methods, Systems, and Compositions for Counting Nucleic Acid Molecules.” The issued claims are directed to detecting a labeled target molecule on a solid support. “We have added another important patent t
PROG Price Returns